← Leaderboards
Carl H. June
University Of Pennsylvania
$35,377,952
Attributed
$54,062,186
Total exposure
25
Grants
21
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $13.3M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$98,652,781 · 29
By mechanism
P01$25,147,187 · 6
U19$22,997,728 · 6
U01$20,923,310 · 3
U54$10,241,790 · 3
R01$9,780,644 · 5
UG3$2,717,473 · 1
Top collaborators
- Vijay Bhoj5 shared
- George Coukos5 shared
- Alfred L. Garfall5 shared
- James F Markmann5 shared
- Michael C. Milone5 shared
- Ali Naji5 shared
- David Porter5 shared
- Yangbing Zhao5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- David Porter$3,923,854
- Andrew R Haas$3,721,334
- Daniel Sterman$5,215,085
- Meenhard Herlyn$50,214,821
- Saar Gill$5,197,347
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsT-LymphocyteImmunotherapySafetyTechnologyMalignant NeoplasmsCellsResistanceEngineeringLaboratoriesDesignResearch PersonnelTumorProgramsIn VivoAutologousMediatingBaseCellular EngineeringInfusion ProceduresCancer ImmunotherapyChimeric Antigen ReceptorCd19 GeneInnovation
Grant awards (120)
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$4,303,502
U01 · FY2025 · AI
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19$2,863,199
P01 · FY2025 · CA · contact PI
Next generation T cell therapies for mutant KRAS solid tumors$2,238,704
UH3 · FY2025 · CA
Core A: Administrative and Clinical Translational Core$391,372
P01 · FY2025 · CA · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$3,825,129
U01 · FY2024 · AI
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19$3,119,164
P01 · FY2024 · CA · contact PI
Next generation T cell therapies for mutant KRAS solid tumors$1,412,213
UG3 · FY2024 · CA
Core A: Administrative and Clinical Translational Core$300,498
P01 · FY2024 · CA · contact PI
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19$2,782,255
P01 · FY2023 · CA · contact PI
Next generation T cell therapies for mutant KRAS solid tumors$1,305,260
UG3 · FY2023 · CA
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$764,364
U01 · FY2023 · AI
Core A: Administrative and Clinical Translational Core$248,019
P01 · FY2023 · CA · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2022 · AI
Directing the metabolic fate of CAR T cells$423,662
R01 · FY2022 · CA · contact PI
Engineering the Next Generation of T Cells$243,750
U54 · FY2022 · CA · contact PI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2021 · AI
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19$2,194,368
P01 · FY2021 · CA · contact PI
Directing the metabolic fate of CAR T cells$432,308
R01 · FY2021 · CA · contact PI
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells$317,421
P01 · FY2021 · CA · contact PI
Core A: Administrative and Biostatistics Core$151,240
P01 · FY2021 · CA · contact PI
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19$1,701,970
P01 · FY2020 · CA · contact PI
Directing the metabolic fate of CAR T cells$432,308
R01 · FY2020 · CA · contact PI
Project 2: Towards a safe and effective AML treatment strategy using anti-CD33 CAR T cells in combination with CAR-resistant hematopoietic stem cells$241,649
P01 · FY2020 · CA · contact PI
Engineering the next generation of T cells$233,103
U54 · FY2020 · CA · contact PI
Determinants of CD8+ T Cell Aging and Reduced Function in B Cell Cancer$121,500
U01 · FY2020 · AG · contact PI
Core A: Administrative and Biostatistics Core$111,965
P01 · FY2020 · CA · contact PI
Engineering the Next Generation of T Cells$6,668,121
U54 · FY2019 · CA · contact PI
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19$2,756,111
P01 · FY2019 · CA · contact PI
Project 1$1,657,050
U54 · FY2019 · CA · contact PI
Admin Core$1,439,766
U54 · FY2019 · CA · contact PI
Directing the metabolic fate of CAR T cells$419,337
R01 · FY2019 · CA · contact PI
Core A: Administrative and Biostatistics Core$151,239
P01 · FY2019 · CA · contact PI
Determinants of CD8+ T Cell Aging and Reduced Function in B Cell Cancer$121,438
U01 · FY2019 · AG · contact PI
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19$92,446
P01 · FY2019 · CA · contact PI
Core A: Administrative and Biostatistics Core$15,408
P01 · FY2019 · CA · contact PI
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19$2,804,200
P01 · FY2018 · CA · contact PI
Directing the metabolic fate of CAR T cells$432,308
R01 · FY2018 · CA · contact PI
Core A: Administrative and Biostatistics Core$151,240
P01 · FY2018 · CA · contact PI
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19$95,306
P01 · FY2018 · CA · contact PI
Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19$2,897,444
P01 · FY2017 · CA · contact PI
Core A: Administrative and Biostatistics Core$148,568
P01 · FY2017 · CA · contact PI
Role of co-receptor modified cells in HIV infection$1,388,771
U01 · FY2016 · AI · contact PI
IMMUNOTHERAPY WITH CAR T CELLS$270,400
R01 · FY2016 · CA · contact PI
CD19 Directed CAR Therapy$237,659
R01 · FY2016 · CA · contact PI
Immunogene Therapy of Mesothelin Expressing Tumors Using Engineered T Cells$167,527
P01 · FY2016 · CA · contact PI
Role of co-receptor modified cells in HIV infection$1,566,653
U01 · FY2015 · AI · contact PI
CD19 Directed CAR Therapy$504,482
R01 · FY2015 · CA · contact PI
IMMUNOTHERAPY WITH CAR T CELLS$270,400
R01 · FY2015 · CA · contact PI
Immunogene Therapy of Mesothelin Expressing Tumors Using Engineered T Cells$167,527
P01 · FY2015 · CA · contact PI
Role of co-receptor modified cells in HIV infection$1,566,653
U01 · FY2014 · AI · contact PI
CD19 Directed CAR Therapy$489,347
R01 · FY2014 · CA · contact PI
IMMUNOTHERAPY WITH CAR T CELLS$262,288
R01 · FY2014 · CA · contact PI
Immunogene Therapy of Mesothelin Expressing Tumors Using Engineered T Cells$161,613
P01 · FY2014 · CA · contact PI
Core E: Molecular Gene Delivery/Modification Core$136,124
P30 · FY2014 · DK · contact PI
Combination immunotherapy with gene modified CD4 and CD8 T cells and stem cells$1,596,110
U19 · FY2013 · AI · contact PI
Role of co-receptor modified cells in HIV infection$1,314,844
U01 · FY2013 · AI · contact PI
Clinical Trials to Evaluate the Safety and Antiviral Effects of High Affinity Gag$640,696
U19 · FY2013 · AI · contact PI
Advancing T cell Therapy for Ovarian Cancer$529,359
P50 · FY2013 · CA
CD19 Directed CAR Therapy$474,213
R01 · FY2013 · CA · contact PI
IMMUNOTHERAPY WITH CAR T CELLS$254,176
R01 · FY2013 · CA · contact PI
Core E: Molecular Gene Delivery/Modification Core$167,889
P30 · FY2013 · DK · contact PI
Immunogene Therapy of Mesothelin Expressing Tumors Using Engineered T Cells$155,699
P01 · FY2013 · CA · contact PI
Administrative Core$82,877
U19 · FY2013 · AI · contact PI
Combination immunotherapy with gene modified CD4 and CD8 T cells and stem cells$1,740,409
U19 · FY2012 · AI · contact PI
Role of co-receptor modified cells in HIV infection$1,287,047
R01 · FY2012 · AI · contact PI
Clinical Trials to Evaluate the Safety and Antiviral Effects of High Affinity Gag$697,584
U19 · FY2012 · AI · contact PI
CD19 Directed CAR Therapy$511,366
R01 · FY2012 · CA · contact PI
Advancing T cell Therapy for Ovarian Cancer$450,053
P50 · FY2012 · CA
IMMUNOTHERAPY WITH CAR T CELLS$270,400
R01 · FY2012 · CA · contact PI
Immunogene Therapy of Mesothelin Expressing Tumors Using Engineered T Cells$167,528
P01 · FY2012 · CA · contact PI
Core E: Molecular Gene Delivery/Modification Core$136,125
P30 · FY2012 · DK · contact PI
Administrative Core$89,899
U19 · FY2012 · AI · contact PI
Combination immunotherapy with gene modified CD4 and CD8 T cells and stem cells$1,787,333
U19 · FY2011 · AI · contact PI
Advancing T cell Therapy for Ovarian Cancer$516,260
P50 · FY2011 · CA
Clinical Trials to Evaluate the Safety and Antiviral Effects of High Affinity Gag$472,751
U19 · FY2011 · AI · contact PI
Administrative Core$151,457
U19 · FY2011 · AI · contact PI
Core E: Molecular Gene Delivery/Modification Core$142,097
P30 · FY2011 · DK · contact PI
Combination immunotherapy with gene modified CD4 and CD8 T cells and stem cells$1,848,744
U19 · FY2010 · AI · contact PI
Advancing T cell Therapy for Ovarian Cancer$542,075
P50 · FY2010 · CA
FACSAria II Cell Sorter for Non-Biohazardous Cells$500,000
S10 · FY2010 · RR · contact PI
Clinical Trials to Evaluate the Safety and Antiviral Effects of High Affinity Gag$496,968
U19 · FY2010 · AI · contact PI
Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells$266,186
R01 · FY2010 · CA · contact PI
Core E: Molecular Gene Delivery/Modification Core$182,469
P30 · FY2010 · DK · contact PI
Immunogene Ther. of Mesothelin Express. Tumors Using Lentiviral Engineered TCells$179,855
P01 · FY2010 · CA · contact PI
Administrative Core$157,489
U19 · FY2010 · AI · contact PI
Combination immunotherapy with gene modified CD4 and CD8 T cells and stem cells$1,967,243
U19 · FY2009 · AI · contact PI
Clinical Trials to Evaluate the Safety and Antiviral Effects of High Affinity Gag$559,030
U19 · FY2009 · AI · contact PI
Lentivirus-based Immunogene Therapy for HIV Infection$459,344
U19 · FY2009 · AI · contact PI
Advancing T cell Therapy for Ovarian Cancer$438,669
P50 · FY2009 · CA
Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells$266,186
R01 · FY2009 · CA · contact PI
Immunogene Ther. of Mesothelin Express. Tumors Using Lentiviral Engineered TCells$173,831
P01 · FY2009 · CA · contact PI
Administrative Core$169,030
U19 · FY2009 · AI · contact PI
Lentivirus-based Immunogene Therapy for HIV Infection$1,931,956
U19 · FY2008 · AI · contact PI
Clinical Trials Engine Lentiviral engineered T cells for HIV$798,675
U19 · FY2008 · AI · contact PI
Culture systems to propogate human T cell subsets$270,520
R01 · FY2008 · CA · contact PI
Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells$266,186
R01 · FY2008 · CA · contact PI
Administrative and Biostatistics Core$220,762
U19 · FY2008 · AI · contact PI
Immunogene Ther. of Mesothelin Express. Tumors Using Lentiviral Engineered TCells$169,269
P01 · FY2008 · CA · contact PI
Lentivirus-based Immunogene Therapy for HIV Infection$1,931,956
U19 · FY2007 · AI · contact PI
Clinical Trials Engine Lentiviral engineered T cells for HIV$907,100
U19 · FY2007 · AI · contact PI
Core--Immunology Facility$298,129
P30 · FY2007 · AI · contact PI
Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells$271,168
R01 · FY2007 · CA · contact PI
Culture systems to propogate human T cell subsets$270,717
R01 · FY2007 · CA · contact PI
Immunogene Ther. of Mesothelin Express. Tumors Using Lentiviral Engineered TCells$170,642
P01 · FY2007 · CA · contact PI
Administrative and Biostatistics Core$83,997
U19 · FY2007 · AI · contact PI
Lentivirus-based Immunogene Therapy for HIV Infection$1,936,423
U19 · FY2006 · AI · contact PI
Clinical Trials Engine Lentiviral engineered T cells for HIV$734,669
U19 · FY2006 · AI · contact PI
Culture systems to propogate human T cell subsets$279,000
R01 · FY2006 · CA · contact PI
Immunotherapy of mesothelin expressing tumors with lentiviral engineered T cells$278,675
R01 · FY2006 · CA · contact PI
Core--Immunology Facility$195,237
P30 · FY2006 · AI · contact PI
Administrative and Biostatistics Core$168,995
U19 · FY2006 · AI · contact PI
Immunogene Ther. of Mesothelin Express. Tumors Using Lentiviral Engineered TCells$98,614
P01 · FY2006 · CA · contact PI
Culture systems to propogate human T cell subsets$68,295
R01 · FY2006 · CA · contact PI
Lentivirus-based Immunogene Therapy for HIV Infection$939,640
U19 · FY2005 · AI
Clinical Trials Engine Lentiviral engineered T cells for HIV$350,835
U19 · FY2005 · AI
Culture systems to propogate human T cell subsets$285,910
R01 · FY2005 · CA
Core--Immunology Facility$189,626
P30 · FY2005 · AI
Administrative and Biostatistics Core$75,756
U19 · FY2005 · AI
Culture systems to propogate human T cell subsets$286,100
R01 · FY2004 · CA
Core--Immunology Facility$181,833
P30 · FY2004 · AI